How does the FDA regulate adaptogens and functional mushroom supplements?

The FDA does not regulate 'adaptogens' as a defined product category — the word does not appear in the Federal Food, Drug, and Cosmetic Act. Functional mushrooms sold as dietary supplements operate under DSHEA, which does not require pre-market approval. The FDA acts after the fact, and its enforcement pattern is consistent: warning letters target disease claims rather than the ingredients themselves. When a product marketed as a functional mushroom supplement makes claims about lowering cholesterol, reducing inflammation, or fighting cancer, the FDA classifies it as an unapproved new drug — not because the mushroom is illegal, but because the claim converts the product from a supplement to a drug under federal law. Lion's mane, reishi, chaga, cordyceps, ashwagandha, and rhodiola products have all drawn warning letters under this enforcement pattern. The mushrooms are legal; the claims are not. In December 2024 the FDA took ingredient-level action for the first time in this space, determining that Amanita muscaria and its constituents do not meet the GRAS standard and are unapproved food additives.

Does the FTC regulate adaptogen and functional mushroom advertising?

Yes — the FTC governs advertising while the FDA governs labeling, and their combined scope covers every consumer-facing surface a brand operates. FTC-FDA coordination on supplement and wellness advertising is an active enforcement tool in 2026, and companies should assume social media and influencer content is fully in scope for both agencies. The FTC's Health Products Compliance Guidance requires that health-related claims be supported by competent and reliable scientific evidence calibrated to the strength of the claim. A paid influencer post describing a mushroom supplement as stress-relieving or immune-boosting carries the same substantiation requirement as the same claim on the product label. There has also been a surge in class-action activity around functional and adaptogen benefit claims, in which plaintiffs argue claims are insufficient in dose or misleading given the available evidence — these suits run independently of agency enforcement and have settled at high cost for brands that could not substantiate their claims.

What was the FDA's December 2024 Amanita muscaria determination and what does it mean for functional mushroom brands?

In December 2024, the FDA determined that Amanita muscaria, its extracts, and certain constituents — muscimol, ibotenic acid, and muscarine — do not meet the GRAS standard and are unapproved food additives, removing the legal basis for product categories that some brands had been marketing as functional mushrooms. The determination has two practical implications for the broader market. First, it clarified the perimeter separating conventional functional mushrooms (reishi, lion's mane, chaga, cordyceps, turkey tail) from the Amanita and psychedelic mushroom categories — conventional functional mushrooms are not affected by the determination. Second, it demonstrated that the FDA will take ingredient-level enforcement action when public health concerns and adverse event reports accumulate, signaling that the agency's DSHEA post-market enforcement posture is active rather than passive. Brands selling products containing Amanita muscaria or its constituents after December 2024 are selling unapproved food additives under current federal law.

How are retailers like Whole Foods and Target enforcing adaptogen and mushroom supplement standards?

Major natural and specialty retailers have become a de facto compliance checkpoint that operates faster than either federal agency. Brands seeking shelf placement in premium retail chains face ingredient permissibility questions, COA verification demands, and GRAS assessments for food and beverage format applications — documentation that the FDA itself rarely requests upfront but that retailers treat as prerequisites. A mushroom supplement brand is as likely to face a compliance challenge from Whole Foods or Target as from the FDA, and the retailer's timeline is immediate rather than reactive. The retailers' enforcement focus includes ingredient permissibility, accurate labeling, and COA documentation — particularly as high-profile product removals for ingredient permissibility violations have raised consumer expectations and retailer accountability in the functional mushroom and adaptogen space.

What documentation do adaptogen and functional mushroom brands need to operate compliantly?

Compliant operations in the adaptogen and functional mushroom category require three documentation systems. First, claim substantiation files for every structure-function claim made on labels, websites, and in advertising — including influencer content — with competent and reliable scientific evidence calibrated to the strength of the claim. These files must be maintained before claims are made and produced on demand in response to FDA inquiry, FTC investigation, or plaintiff discovery. Second, GRAS documentation for each ingredient used in food and beverage formats — functional mushroom coffees, gummies, and ready-to-drink beverages require GRAS substantiation under specific conditions of use, which does not follow automatically from supplement use qualification. Third, batch-level COAs confirming ingredient identity, active compound concentrations, and contaminant absence for each production run — not a single launch COA, but batch-specific documentation retrievable by lot number for retailer audits and regulatory inspections. Businesses with these documentation systems in place are in a materially different compliance position from those relying on industry norms and a low probability of enforcement.

Adaptogens Under the Microscope

Category: Business Learning Center

Author: Joy

Date: May 7, 2026

The word "adaptogen" does not appear anywhere in the Federal Food, Drug, and Cosmetic Act. The FDA has not defined it, approved it, or regulated it as a product category. That ambiguity helped build a booming market — and it is now drawing the attention of two federal agencies, a surge of class-action plaintiffs, and major retailers who are enforcing standards the FDA itself rarely demands up front.

Functional mushrooms sit at the center of this scrutiny. Reishi, lion's mane, chaga, cordyceps, and turkey tail are among the most widely marketed adaptogenic ingredients in the supplement and functional food space. Functional mushroom food and beverage products reached approximately $1.9 billion in 2025 and are projected to exceed $2.2 billion by end of 2026. That kind of growth draws regulatory attention even when specific rules don't yet exist.

The FDA's Role — and Its Limits

Functional mushrooms sold as dietary supplements operate under DSHEA, the same framework governing vitamins and herbal products. The FDA does not pre-approve these products before they reach the market. It acts after the fact — when adverse events are reported, when labeling crosses a line, or when agency resources allow.

Since adaptogen ingredients are not recognized as pharmaceutical drugs, there are no formal requirements a product must meet to receive the label "adaptogen," and many manufacturers use it regardless of the ingredient's purity or properties. That gap has allowed a wide range of product quality and claim aggressiveness to coexist on the same retail shelf.

When the FDA does act, the enforcement pattern is consistent. Warning letters have targeted disease claims — not the ingredients themselves. FDA actions against companies selling lion's mane, reishi, chaga, and cordyceps products cited language including claims about lowering cholesterol, reducing inflammation, and fighting cancer. Ashwagandha and rhodiola were caught in the same enforcement sweep, with the FDA finding that products making disease treatment claims were unapproved new drugs under federal law. The mushrooms were legal. The claims were not.

The FTC's Parallel Enforcement Track

The FDA governs labeling. The FTC governs advertising — and in practice, that means everything from website copy and email campaigns to social media posts and influencer content. Both agencies coordinate, and their combined scope covers every consumer-facing surface a brand operates.

FTC-FDA coordination on supplement and wellness advertising remains an active enforcement tool, and companies should assume that social media and influencer content is fully in scope for both agencies in 2026. The FTC's Health Products Compliance Guidance requires that health-related claims be supported by competent and reliable scientific evidence, calibrated to the strength of the claim. A post from a paid influencer describing a mushroom supplement as stress-relieving or immune-boosting carries the same substantiation requirement as a claim on the label.

There has been a surge in class action activity around functional and nootropic/adaptogen benefit claims, in which plaintiffs argue that the claims are insufficient in dose or misleading given the available evidence. These suits do not wait for FDA enforcement — they run independently and have settled at high cost for brands that could not substantiate their claims.

The Retail Enforcement Layer

Major natural and specialty retailers have become a de facto compliance checkpoint that operates faster than either federal agency. Brands are as likely to face a challenge from commercial retailers like Whole Foods or Target — both of whom are more vigilant than the FDA about ensuring that ingredients are legally permissible — as they are from the FDA itself.

For mushroom and adaptogen brands seeking shelf placement in premium retail, ingredient permissibility documentation, GRAS assessments for food and beverage applications, and Certificate of Analysis verification are increasingly prerequisites — not optional quality additions.

Where the Lines Are Being Drawn

The FDA drew one hard line in December 2024 that is directly relevant to the mushroom market. The FDA determined that Amanita muscaria, its extracts, and certain constituents, including muscimol, ibotenic acid, and muscarine, do not meet the GRAS standard and are unapproved food additives, thereby removing the legal basis for an entire product category that some brands had marketed as functional mushrooms. That action clarified the perimeter for conventional functional mushrooms — but it also demonstrated the agency's willingness to move when public health concerns and adverse event reports accumulate.

Outside the U.S., the regulatory picture is tightening further. Between 2023 and 2025, global authorities focused not only on ashwagandha but also on kratom, Tongkat Ali, and green tea extracts, reflecting heightened safety concerns and stricter consumer protection standards across multiple jurisdictions. Brands operating in international markets face a layered compliance problem that is only getting more complex.

What Compliant Operations Look Like

The regulatory exposure in this category comes from three sources: disease claims on labels or in advertising, ingredient use in food and beverage formats without a defensible GRAS position, and substantiation gaps that leave structure-function claims unsupported if challenged.

Businesses that have built documentation systems — batch-level COAs, substantiation files for every active claim, ingredient identity verification — are in a materially different compliance position from those relying on industry norms and a low probability of enforcement. The latter is a posture, not a program.

Contact Qredible today to learn how our quality management solutions help functional mushroom and adaptogen businesses implement comprehensive claim-substantiation documentation, maintain ingredient-verification systems, and build the compliance infrastructure necessary to meet the standards of both regulatory agencies and major retail partners in an increasingly scrutinized market.